Sickle-cell disease

[1]  M. Gladwin,et al.  Pulmonary complications of sickle cell disease. , 2012, American journal of respiratory and critical care medicine.

[2]  R. Ware,et al.  Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). , 2012, Blood.

[3]  K. Marsh,et al.  High mortality from Plasmodium falciparum malaria in children living with sickle cell anemia on the coast of Kenya , 2010, Blood.

[4]  B. Bain,et al.  Significant haemoglobinopathies: guidelines for screening and diagnosis , 2010, British journal of haematology.

[5]  E. Terpos,et al.  The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). , 2010, Blood.

[6]  K. Marsh,et al.  Malaria in patients with sickle cell anemia: burden, risk factors, and outcome at the outpatient clinic and during hospitalization. , 2010, Blood.

[7]  J. Stockman.  Systematic Review: Hydroxyurea for the Treatment of Adults with Sickle Cell Disease , 2010 .

[8]  Scott T. Miller,et al.  Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. , 2010, The Journal of pediatrics.

[9]  Jonathan D. Powell,et al.  Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. , 2009, The New England journal of medicine.

[10]  D. Nathan,et al.  Sickle cell disease and stroke. , 2009, Blood.

[11]  S. Thein,et al.  Extracranial Internal Carotid Arterial Disease in Children with Sickle Cell Disease. , 2009 .

[12]  L. Savale,et al.  Prospective Multicentric Survey On Pulmonary Hypertension (PH) in Adults with Sickle Cell Disease. , 2009 .

[13]  B. Pace,et al.  Hydroxyurea Generates Nitric Oxide in Human Erythroid Cells: Mechanisms for γ-Globin Gene Activation , 2009, Experimental biology and medicine.

[14]  F. Roudot-thoraval,et al.  A randomized, controlled clinical trial of ketoprofen for sickle-cell disease vaso-occlusive crises in adults. , 2009, Blood.

[15]  K. Marsh,et al.  Bacteraemia in Kenyan children with sickle-cell anaemia: a retrospective cohort and case–control study , 2009, The Lancet.

[16]  B. Barton,et al.  Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. , 2009, Journal of the National Medical Association.

[17]  M. Gladwin,et al.  Prospective echocardiography assessment of pulmonary hypertension and its potential etiologies in children with sickle cell disease. , 2009, The American journal of cardiology.

[18]  T. Wellems,et al.  The impact of malaria parasitism: from corpuscles to communities. , 2009, The Journal of clinical investigation.

[19]  J. Shults,et al.  Silent infarcts in young children with sickle cell disease , 2009, British journal of haematology.

[20]  Robert Adams,et al.  Hemodynamic Etiology of Elevated Flow Velocity and Stroke in Sickle-Cell Disease , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[21]  Edward R. Smith,et al.  Pial synangiosis in patients with moyamoya syndrome and sickle cell anemia: perioperative management and surgical outcome. , 2009, Neurosurgical focus.

[22]  M. Gladwin,et al.  Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell disease: association with hemolysis and hemoglobin oxygen desaturation , 2008, Haematologica.

[23]  F. Sampaio,et al.  Treatment of recurrent priapism in sickle cell anemia with finasteride: a new approach. , 2004, Urology.

[24]  D. Persons,et al.  Hematopoietic stem cell gene transfer for the treatment of hemoglobin disorders. , 2009, Hematology. American Society of Hematology. Education Program.

[25]  S. Thein,et al.  The effects of air quality on haematological and clinical parameters in children with sickle cell anaemia , 2009, Annals of Hematology.

[26]  B. Bain.  Neonatal/newborn haemoglobinopathy screening in Europe and Africa , 2008, Journal of Clinical Pathology.

[27]  Renee F Wilson,et al.  Hydroxyurea for Sickle Cell Disease: A Systematic Review for Efficacy and Toxicity in Children , 2008, Pediatrics.

[28]  C. Delacourt,et al.  G6PD deficiency, absence of (cid:1) -thalassemia, and hemolytic rate at baseline are significant independent risk factors for abnormally high cerebral velocities in patients with sickle cell anemia , 2008 .

[29]  M. DeBaun,et al.  Sibling history of asthma is a risk factor for pain in children with sickle cell anemia , 2008, American journal of hematology.

[30]  J. Hirschhorn,et al.  DNA polymorphisms at the BCL11A, HBS1L-MYB, and β-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease , 2008, Proceedings of the National Academy of Sciences.

[31]  A. Pizzey,et al.  Microvesicles in haemoglobinopathies offer insights into mechanisms of hypercoagulability, haemolysis and the effects of therapy , 2008, British journal of haematology.

[32]  P. Jouannet,et al.  Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males , 2008, Haematologica.

[33]  B. Pollock,et al.  National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. , 2008, Annals of internal medicine.

[34]  B. Aygun,et al.  Resolution of chronic hypoxemia in pediatric sickle cell patients after treatment with hydroxyurea , 2008, Pediatric blood & cancer.

[35]  Matthew Darlison,et al.  Global epidemiology of haemoglobin disorders and derived service indicators. , 2008, Bulletin of the World Health Organization.

[36]  E. Vichinsky,et al.  Advances in clinical research in sickle cell disease , 2008, British journal of haematology.

[37]  P. Hernigou,et al.  Percutaneous Implantation of Autologous Bone Marrow Osteoprogenitor Cells as Treatment of Bone Avascular Necrosis Related to Sickle Cell Disease , 2008, The open orthopaedics journal.

[38]  F. Roudot-thoraval,et al.  Pulmonary Hypertension and Cor Pulmonale during Severe Acute Chest Syndrome in Sickle Cell Disease at a Glance Commentary , 2022 .

[39]  J. Elion,et al.  Erythroid adhesion molecules in sickle cell disease: effect of hydroxyurea. , 2008, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine.

[40]  A. Ashley-Koch,et al.  Pulmonary hypertension associated with sickle cell disease: Clinical and laboratory endpoints and disease outcomes , 2008, American journal of hematology.

[41]  C. Moore,et al.  Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension , 2008, Haematologica.

[42]  D. Rees,et al.  Serum lactate dehydrogenase activity as a biomarker in children with sickle cell disease , 2007, British journal of haematology.

[43]  E. Souied,et al.  Retinal photocoagulation for proliferative sickle cell retinopathy: A prospective clinical trial with new sea fan classification. , 2008, European journal of ophthalmology.

[44]  M. Bhatia,et al.  Hematopoietic cell transplantation for thalassemia and sickle cell disease: past, present and future , 2008, Bone Marrow Transplantation.

[45]  Marius Wernig,et al.  Treatment of Sickle Cell Anemia Mouse Model with iPS Cells Generated from Autologous Skin , 2007, Science.

[46]  W. Klitz,et al.  Confirmation of an Association Between the TNF(−308) Promoter Polymorphism and Stroke Risk in Children With Sickle Cell Anemia , 2007, Stroke.

[47]  R. Ware,et al.  Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. , 2007, Blood.

[48]  T. Spector,et al.  Intergenic variants of HBS1L-MYB are responsible for a major quantitative trait locus on chromosome 6q23 influencing fetal hemoglobin levels in adults , 2007, Proceedings of the National Academy of Sciences.

[49]  M. Steinberg,et al.  Hemoglobin SE disease—A concise review , 2007, American journal of hematology.

[50]  S. Thein,et al.  The linear effects of α‐thalassaemia, the UGT1A1 and HMOX1 polymorphisms on cholelithiasis in sickle cell disease , 2007, British journal of haematology.

[51]  W. Schaffner,et al.  Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[52]  T. Agbenyega,et al.  Hemoglobin variants and disease manifestations in severe falciparum malaria. , 2007, JAMA.

[53]  K. Mekeel,et al.  Liver transplantation in children with sickle‐cell disease , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[54]  S. Thein,et al.  The associations between air quality and the number of hospital admissions for acute pain and sickle‐cell disease in an urban environment , 2007, British journal of haematology.

[55]  P. Marks,et al.  A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease , 2007, British journal of haematology.

[56]  K. Marsh,et al.  Sickle cell disease in Africa: burden and research priorities , 2007, Annals of tropical medicine and parasitology.

[57]  J. Stockman.  Dysregulated Arginine Metabolism, Hemolysis-Associated Pulmonary Hypertension, and Mortality in Sickle Cell Disease , 2007 .

[58]  M. Gladwin,et al.  Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. , 2007, Blood reviews.

[59]  William O Ntim,et al.  Diastolic dysfunction is an independent risk factor for death in patients with sickle cell disease. , 2007, Journal of the American College of Cardiology.

[60]  I. Scott,et al.  Intravitreal bevacizumab (Avastin) injection associated with regression of retinal neovascularization caused by sickle cell retinopathy. , 2006, Acta ophthalmologica Scandinavica.

[61]  E. Vichinsky,et al.  Physical therapy alone compared with core decompression and physical therapy for femoral head osteonecrosis in sickle cell disease. Results of a multicenter study at a mean of three years after treatment. , 2006, The Journal of bone and joint surgery. American volume.

[62]  M. Gladwin.  Deconstructing endothelial dysfunction: soluble guanylyl cyclase oxidation and the NO resistance syndrome. , 2006, The Journal of clinical investigation.

[63]  F. Vargha-Khadem,et al.  Physiological correlates of intellectual function in children with sickle cell disease: hypoxaemia, hyperaemia and brain infarction. , 2006, Developmental science.

[64]  M. Gladwin,et al.  Cerebrovascular disease associated with sickle cell pulmonary hypertension , 2006, American journal of hematology.

[65]  C. Moore,et al.  Pulmonary hypertension in patients with sickle cell disease: a longitudinal study , 2006, British journal of haematology.

[66]  R. Adams,et al.  Pathophysiology and treatment of stroke in sickle-cell disease: present and future , 2006, The Lancet Neurology.

[67]  M. Garenne,et al.  Health transitions in sub-Saharan Africa: overview of mortality trends in children under 5 years old (1950-2000). , 2006, Bulletin of the World Health Organization.

[68]  M. Steinberg,et al.  Modifier genes and sickle cell anemia , 2006, Current opinion in hematology.

[69]  R. Ware,et al.  Enalapril and hydroxyurea therapy for children with sickle nephropathy , 2005, Pediatric blood & cancer.

[70]  S. Thein,et al.  Windy weather and low humidity are associated with an increased number of hospital admissions for acute pain and sickle cell disease in an urban environment with a maritime temperate climate , 2005, British journal of haematology.

[71]  L. Farrer,et al.  Hemolysis-associated Priapism in Sickle Cell Disease , 2005 .

[72]  M. Gladwin,et al.  Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension , 2005, British journal of haematology.

[73]  R. Snow,et al.  Sickle cell trait and the risk of Plasmodium falciparum malaria and other childhood diseases. , 2005, The Journal of infectious diseases.

[74]  D. Granger,et al.  Endothelial cell NADPH oxidase mediates the cerebral microvascular dysfunction in sickle cell transgenic mice , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[75]  John C Bischof,et al.  Critical role of endothelial cell activation in hypoxia-induced vasoocclusion in transgenic sickle mice. , 2005, American journal of physiology. Heart and circulatory physiology.

[76]  M. Gladwin,et al.  The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. , 2005, JAMA.

[77]  Paola Sebastiani,et al.  Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia , 2005, Nature Genetics.

[78]  G. Serjeant.  Mortality from sickle cell disease in Africa , 2005, BMJ : British Medical Journal.

[79]  K. Hofman,et al.  A case for developing North-South partnerships for research in sickle cell disease. , 2005, Blood.

[80]  E. Neufeld,et al.  Hemoglobin Jamaica plain--a sickling hemoglobin with reduced oxygen affinity. , 2004, The New England journal of medicine.

[81]  R. Adams,et al.  Declining stroke rates in Californian children with sickle cell disease. , 2004, Blood.

[82]  Andrew J Tatem,et al.  The global distribution and population at risk of malaria: past, present, and future. , 2004, The Lancet. Infectious diseases.

[83]  W. Klitz,et al.  Gene interactions and stroke risk in children with sickle cell anemia. , 2004, Blood.

[84]  Marvin D Nelson,et al.  Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. , 2004, Blood.

[85]  H. Farber,et al.  Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. , 2004, The New England journal of medicine.

[86]  Scott T. Miller,et al.  Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination. , 2003, The Journal of pediatrics.

[87]  R. Nagel,et al.  The paradox of hemoglobin SC disease. , 2003, Blood reviews.

[88]  M. C. Rahimy,et al.  Effect of a comprehensive clinical care program on disease course in severely ill children with sickle cell anemia in a sub-Saharan African setting. , 2003, Blood.

[89]  J. Bischof,et al.  Transgenic sickle mice have vascular inflammation. , 2003, Blood.

[90]  C. Pegelow,et al.  Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. , 2003, JAMA.

[91]  A. Cooper,et al.  Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease. , 2003, JAMA.

[92]  A. Wade,et al.  Nocturnal oxygen saturation and painful sickle cell crises in children. , 2003, Blood.

[93]  A. Omari,et al.  Malaria chemoprophylaxis in sickle cell disease. , 2003, The Cochrane database of systematic reviews.

[94]  J. Scheinman.  Sickle cell disease and the kidney. , 2003, Seminars in nephrology.

[95]  M. Gladwin,et al.  Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. , 2002 .

[96]  B. Coller,et al.  Primary role for adherent leukocytes in sickle cell vascular occlusion: A new paradigm , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[97]  P. Frenette.  Sickle cell vaso-occlusion: multistep and multicellular paradigm , 2002, Current opinion in hematology.

[98]  R. Nagel,et al.  Correction of Sickle Cell Disease in Transgenic Mouse Models by Gene Therapy , 2001, Science.

[99]  K. Ataga,et al.  Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: A randomized controlled trial. , 2001, JAMA.

[100]  J. Eckman.  Techniques for blood administration in sickle cell patients. , 2001, Seminars in hematology.

[101]  G. Vercellotti,et al.  Reperfusion injury pathophysiology in sickle transgenic mice. , 2000, Blood.

[102]  P. V. Ichinsky,et al.  Causes and Outcomes of the Acute Chest Syndrome in Sickle Cell Disease , 2000 .

[103]  Bruno J. Strasser,et al.  "Sickle Cell Anemia, a Molecular Disease" , 1999, Science.

[104]  R. Nagel,et al.  HbS-oman heterozygote: a new dominant sickle syndrome. , 1998, Blood.

[105]  Scott T. Miller,et al.  Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. , 1998, The New England journal of medicine.

[106]  J. Reisch,et al.  Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease. , 1998, Blood.

[107]  Scott T. Miller,et al.  Cerebrovascular accidents in sickle cell disease: rates and risk factors. , 1998, Blood.

[108]  E. Kopecky,et al.  Randomised trial of oral morphine for painful episodes of sickle-cell disease in children , 1997, The Lancet.

[109]  H. Bunn.  Pathogenesis and treatment of sickle cell disease. , 1997, The New England journal of medicine.

[110]  Y. Ichinose.  [Pulmonary complications in hematological diseases]. , 1997, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[111]  E. Vichinsky,et al.  Natural history of blood pressure in sickle cell disease: risks for stroke and death associated with relative hypertension in sickle cell anemia. , 1997, The American journal of medicine.

[112]  Alberto Piazza,et al.  The History and Geography of Human Genes: Abridged paperback Edition , 1996 .

[113]  M. Kerstein,et al.  Leg ulcers in patients with sickle cell disease. , 1996, Advances in wound care : the journal for prevention and healing.

[114]  P. Lane.  Sickle cell disease. , 1996, Pediatric clinics of North America.

[115]  C. Pegelow,et al.  Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease. , 1995, Blood.

[116]  P. Libby,et al.  Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. , 1995, The Journal of clinical investigation.

[117]  M L Terrin,et al.  Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. , 1995, The New England journal of medicine.

[118]  O. Platt,et al.  Mortality in sickle cell disease. Life expectancy and risk factors for early death. , 1994, The New England journal of medicine.

[119]  D. McIntire,et al.  High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. , 1994, The New England journal of medicine.

[120]  J. Flint,et al.  The population genetics of the haemoglobinopathies. , 1993, Bailliere's clinical haematology.

[121]  R. Hebbel,et al.  Hydroxyl radical formation by sickle erythrocyte membranes: role of pathologic iron deposits and cytoplasmic reducing agents. , 1991, Blood.

[122]  S. Baruchel,et al.  Sickle cell disease in a patient with sickle cell trait and compound heterozygosity for hemoglobin S and hemoglobin Quebec-Chori. , 1991, The New England journal of medicine.

[123]  A. Kulozik,et al.  Two different forms of homozygous sickle cell disease occur in Saudi Arabia , 1991, British journal of haematology.

[124]  E Vichinsky,et al.  Pain in sickle cell disease. Rates and risk factors. , 1991, The New England journal of medicine.

[125]  R. A. Johnson,et al.  Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. , 1990, The New England journal of medicine.

[126]  T. Gross,et al.  Newborn screening for sickle cell disease. , 1989, Pediatrics.

[127]  S. Moncada,et al.  Vascular endothelial cells synthesize nitric oxide from L-arginine , 1988, Nature.

[128]  A. Schechter,et al.  Levels of fetal hemoglobin necessary for treatment of sickle cell disease. , 1988, The New England journal of medicine.

[129]  M. Vidaud,et al.  Hemoglobin S Antilles: a variant with lower solubility than hemoglobin S and producing sickle cell disease in heterozygotes. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[130]  A. Kulozik,et al.  SICKLE CELL DISEASE IN ORISSA STATE, INDIA , 1986, The Lancet.

[131]  E Vichinsky,et al.  Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. , 1986, The New England journal of medicine.

[132]  T. Huisman,et al.  DNA sequence variation associated with elevated fetal G gamma globin production. , 1985, Blood.

[133]  A. Schechter,et al.  Hemoglobin S polymerization: primary determinant of the hemolytic and clinical severity of the sickling syndromes. , 1985, Blood.

[134]  A. Look,et al.  Bone-marrow transplantation in a patient with sickle-cell anemia. , 1984, The New England journal of medicine.

[135]  G. Maude,et al.  Prevention of pneumococcal infection in children with homozygous sickle cell disease. , 1984, British medical journal.

[136]  S. Orkin,et al.  Hydroxyurea increases fetal hemoglobin production in sickle cell anemia. , 1984, Transactions of the Association of American Physicians.

[137]  J. Clegg,et al.  The interaction of alpha-thalassemia and homozygous sickle-cell disease. , 1982, The New England journal of medicine.

[138]  G. Serjeant,et al.  Climate and painful crisis of sickle-cell disease in Jamaica. , 1976, British medical journal.

[139]  W. Moo-Penn,et al.  The presence of hemoglobin S and C Harlem in an individual in the United States. , 1975, Blood.

[140]  A. Allison,et al.  Protection Afforded by Sickle-cell Trait Against Subtertian Malarial Infection , 1954, British medical journal.

[141]  F. Eirich,et al.  X-ray and solubility studies of the haemoglobin of sickle-cell anaemia patients. , 1951, Nature.

[142]  G. S. Graham.  A CASE OF SICKLE CELL ANEMIA WITH NECROPSY , 1924 .

[143]  V. P. Sydenstricker.  FURTHER OBSERVATIONS ON SICKLE CELL ANEMIA , 1924 .